Shots: Brii Bio launched amubarvimab + romlusevimab in China as a long-acting COVI...
Shots: The companies have entered into a 3yr. agreement to manufacture AstraZeneca...
Shots: The NDA was submitted based on the P-II/III (EPIC-HR) & (EPIC-SR) trial...
Shots: The P-III (VAT08) trial evaluated an adjuvanted bivalent D614 & B...
Shots: The first patient has been dosed in a P-III study evaluating SCB-2019 (CpG...
Shots: The EUA was based on the P-II/III trial to evaluate the 10µg booster...